PT  - JOURNAL ARTICLE
AU  - Tessel M. van Rossen
AU  - Rogier E. Ooijevaar
AU  - Christina M.J.E. Vandenbroucke-Grauls
AU  - Olaf M. Dekkers
AU  - Ed. J. Kuijper
AU  - Josbert J. Keller
AU  - Joffrey van Prehn
TI  - GRADING prognostic factors for severe and recurrent <em>Clostridioides difficile</em> infection: expected and unexpected findings. A systematic review
AID  - 10.1101/2021.06.22.21259313
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.22.21259313
4099  - http://medrxiv.org/content/early/2021/06/25/2021.06.22.21259313.short
4100  - http://medrxiv.org/content/early/2021/06/25/2021.06.22.21259313.full
AB  - Background Clostridioides difficile infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide a significant burden for both patients and the healthcare system. Treatment consists of oral antibiotics. Fidaxomicin, bezlotoxumab and fecal microbiota transplantion (FMT) reduce the number of recurrences compared to vancomycin, but are more costly. Identifying patients diagnosed with initial CDI who are at increased risk of developing sCDI/rCDI could lead to more cost-effective therapeutic choices.Objectives In this systematic review we aimed to identify clinical prognostic factors associated with an increased risk of developing sCDI or rCDI.Methods PubMed, Embase, Emcare, Web of Science and COCHRANE Library databases were searched from database inception through March, 2021. Study selection was performed by two independent reviewers on the basis of predefined selection criteria; conflicts were resolved by consensus. Cohort and case-control studies providing an analysis of clinical or laboratory data to predict sCDI/rCDI in patients ≥18 years diagnosed with CDI, were included. Risk of bias was assessed with the Quality in Prognostic Research (QUIPS) tool and the quality of evidence by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies. Overview tables of prognostic factors were constructed to assess the number of studies and the respective direction of an association (positive, negative, or no association).Results and conclusions 136 studies were included for final analysis. Higher age and the presence of multiple comorbidities were prognostic factors for sCDI. Identified risk factors for rCDI were higher age, healthcare-associated CDI, prior hospitalization, PPIs started during/after CDI diagnosis and previous rCDI. Some variables that were found as risk factors for sCDI/rCDI in previous reviews were not confirmed in the current review, which can be attributed to differences in methodology. Risk stratification for sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.Competing Interest StatementTvR was supported by Netherlands Organization for Health Research and Development (ZonMw) grant Goed Gebruik Geneesmiddelen, project number 848016009. JK and EK received a research grant from Vedanta Biosciences (Boston, USA). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. All other authors: no conflicts of interest to disclose.Funding StatementTvR was supported by Netherlands Organization for Health Research and Development (ZonMw) grant Goed Gebruik Geneesmiddelen, project number 848016009. JK and EK received a research grant from Vedanta Biosciences (Boston, USA). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. All other authors: no conflicts of interest to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable (systematic review)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable (systematic review)